NDT Pharmaceuticals, Inc. engages in the business of developing nutraceutical and pharmaceutical products. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2006-12-14. The firm has acquired all rights under a Sponsored Research Agreement with the University of Pennsylvania, including rights to use the University's Nanoscale Particle Complex (NPC) technology. The intellectual property includes an applicable biotechnology asset base, including the Nanoscale Particle Complex (NPC) technology, which represents phospholipid-based nano-encapsulation delivery systems that create instant delivery of payloads into the bloodstream, beginning through the membranes of the mouth. Encapsulated actives are protected from destruction in the highly acidic environment of the stomach until they reach the small intestine. The NPC technology also incorporates a potent active ingredient that stimulates repair of damaged cell tissue branded by the Company as Cell Armor.